

GROUP'S NAME: (sugere-se que o nome fique a 2 linhas, no máximo 3 linhas – 57 caracteres, sem espaços)

Cancer Genetics Group

PROJECTS WITH EXTERNAL FUNDING

PRECISER – “Preclinical validation of the efficacy of combined inhibition of EGFR and STAT3 for ETS-rearranged prostate carcinomas”; (COMPETE2030-FEDER-00721400); Budget: 203,649 € (2026-2028) (PI: Paula Paulo)

Description (2000 caracteres, sem espaços)

Prostate cancer (PCa) is a major health concern worldwide. This project seeks to revolutionize our understanding and treatment of PCa, steering in a new era of precision medicine. With a multidisciplinary team, we will combine ground-breaking *in vitro*, *in vivo* and ex vivo approaches to validate the efficacy of a therapy targeting 10% of the aggressive PCa, paving the way for future clinical trials repurposing EGFR and STAT3 inhibitors.

PRUNE2 – “PRUNE2 gene as a novel dual-role biomarker for prostate cancer inherited predisposition and therapy response”; FCT (2023.01928.RESTART); Budget: 49,800€ (2023-2025) (PI: Andreia Brandão)

Description (2000 caracteres, sem espaços)

Building on previous findings, this project aims to combine genomic, transcriptomic, and computational approaches to consolidate PRUNE2 as a novel cancer predisposing gene for prostate cancer, and to evaluate its potential as a predictive biomarker.